thalidomide has been researched along with marizomib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Chauhan, D; Ciccarelli, B; Palladino, MA; Richardson, PG; Singh, AV | 1 |
| Goldschmidt, H; Moehler, T | 1 |
| Abe, M; Fujii, S | 1 |
| Mateos, MV; Ocio, EM; San Miguel, JF | 1 |
| Kuroda, J | 1 |
| Anderson, KC; Chauhan, D; Das, DS; Ray, A; Richardson, P; Song, Y; Trikha, M | 1 |
| Anderson, KC; Chanan-Khan, AA; Chauhan, D; Hofmeister, CC; Jakubowiak, AJ; Kaufman, JL; Laubach, JP; Reich, S; Richardson, PG; Talpaz, M; Trikha, M; Zimmerman, TM | 1 |
| Moreau, P; Rajkumar, SV | 1 |
3 review(s) available for thalidomide and marizomib
| Article | Year |
|---|---|
Therapy of relapsed and refractory multiple myeloma.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Lactones; Lenalidomide; Middle Aged; Multiple Myeloma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Secondary Prevention; Thalidomide | 2011 |
Novel generation of agents with proven clinical activity in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factors; Lactones; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrroles; Recurrence; Thalidomide; Treatment Outcome | 2013 |
[Current status of clinical trials of novel agents for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Approval; Drug Discovery; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lactones; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Pyrroles; Thalidomide; Vorinostat | 2014 |
1 trial(s) available for thalidomide and marizomib
| Article | Year |
|---|---|
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lactones; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Pyrroles; Recurrence; Thalidomide | 2016 |
4 other study(ies) available for thalidomide and marizomib
| Article | Year |
|---|---|
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; In Vitro Techniques; Lactones; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Proteasome Inhibitors; Pyrroles; Thalidomide; Xenograft Model Antitumor Assays | 2010 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lactones; Mice, SCID; Multiple Myeloma; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Proteasome Inhibitors; Pyrroles; RNA, Small Interfering; Thalidomide; Transplantation, Heterologous; Ubiquitin-Protein Ligases | 2015 |
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide | 2016 |